Kiniksa Pharmaceuticals International (KNSA) Projected to Announce Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is projected to announce its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of $0.30 per share and revenue of $226.4880 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The business had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.11 EPS. On average, analysts expect Kiniksa Pharmaceuticals International to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $62.84 on Monday. The stock has a market capitalization of $4.83 billion, a PE ratio of 69.82 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 1-year low of $26.27 and a 1-year high of $67.53. The firm has a 50-day moving average price of $56.87 and a two-hundred day moving average price of $50.03.

Wall Street Analyst Weigh In

KNSA has been the topic of several research analyst reports. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Finally, Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Kiniksa Pharmaceuticals International has an average rating of “Buy” and a consensus target price of $68.00.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total value of $656,259.90. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction on Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the sale, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at $2,623,481.30. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 628,427 shares of company stock valued at $32,833,228 over the last ninety days. Insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Mark Sheptoff Financial Planning LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after purchasing an additional 250 shares during the period. Mariner LLC lifted its stake in Kiniksa Pharmaceuticals International by 2.0% in the fourth quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after buying an additional 266 shares during the period. Virtus Investment Advisers LLC boosted its holdings in Kiniksa Pharmaceuticals International by 2.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock worth $678,000 after buying an additional 406 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in Kiniksa Pharmaceuticals International by 7.1% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after buying an additional 508 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.